XOlactaThe power and potential of XOlacta
XOlacta contains a revolutionary peptide compound, loaded into a novel drug delivery platform — milk exosomes — which are able to signal, target and deliver vital therapies to the exact site where they’re needed most.
HOW IT WORKSXOlacta
1. Loading
Our uniquely isolated milk-derived exosomes are loaded with our αct-11 peptide to create a powerful new drug, XOlacta.
2. Homing
When orally administered, XOlacta is systemically bioavailable and is delivered where it's needed most—to the cells in injured tissues.
3. Delivery
The αCt-11 peptides are released into cells, arresting the bystander effect to prevent the cascade of cell death and scar formation.
APPLICATIONSLife-changing benefits for patients
We’re currently investigating the use of XOlacta as an orally-administered cardio protectant and whole-body protection for both prophylactic and post-exposure use against lethal, therapeutic and background radiation.
CARDIO PROTECTANTReducing fibrosis (scarring) post myocardial infarction
FULL BODY RADIOPROTECTANTProtecting healthy cells during radiation treatment.
MEDICAL COUNTERMEASURETreating exposure to high doses of ionizing radiation.
PROACTIVE RADIATION PROTECTANTProtection from high levels of background radiation
“Milk Exosomes represent a naturally occurring, orally administered drug delivery platform capable of delivering fragile peptides directly to the site of action. Using this revolutionary technology, Tiny Cargo is capable of addressing the most deadly indications the world has ever known – from fatal radiation exposure to myocardial infarction.”
Spencer Marsh, Ph.D.
Chief Scientific Officer
CARDIO PROTECTANT Reducing cardiac injury following myocardial infarction
The leading cause of death in the western world is a heart attack, or myocardial infarction- currently, there are no effective therapies that stop fibrotic progression after a heart attack; XOlacta is a first in class therapy capable of addressing this deficit.
Injured cardiac tissue preferentially takes up orally-administered milk exosomes. Loaded with our αCT-11 peptide, XOlacta delivers targeted cardioprotection directly to the site of injury — effective even when administered after the event.
FULL BODY RADIOPROTECTANTProtecting healthy cells during radiation exposure
The side effects of radiation exposure during cancer treatment can be devastating, yet there are currently limited treatment options to address tissue injury sustained during radiotherapy.
XOlacta is capable of protecting healthy tissues from radiation damage without extending that protection to cancer cells — representing a potentially life-changing advance for cancer patients undergoing radiotherapy.
MEDICAL COUNTERMEASURETreating exposure to high doses of ionizing radiation
We live in a nuclear world, yet currently there are zero treatments for exposures to high doses of ionizing radiation — we aim to change that.
FDA 'Animal Rule' Regulatory path—Approval estimated Q2 2027
Fast and effective in lethal radiation studies
24hrs
Window
↑ 40%+
Survival rates
Pre-clinical studies show an increase in survival rates of 40% - 70% from 1 dose of XOlacta, when given before or up to 24 hours following exposure.
RESOURCESLatest publications
